30.8 C
Vientiane
Sunday, June 29, 2025
spot_img
Home Blog Page 147

Let There Be Light: Vivid Sydney 2025 Kicks Off

SYDNEY, May 23, 2025 /PRNewswire/ — The Harbour City has awakened in colour and creativity tonight as Vivid Sydney 2025, Australia’s largest event, has officially begun for its 15th year. Under this year’s theme of Dream, a world class curation of Light, Ideas, Music and Food await festivalgoers over 23 nights, until Saturday, 14 June.

Vivid Sydney 2025, Sydney Opera House Lighting Of The Sails. Kiss Of Light by David McDiarmid. Credit - Destination NSW
Vivid Sydney 2025, Sydney Opera House Lighting Of The Sails. Kiss Of Light by David McDiarmid. Credit – Destination NSW

This year, the festival comprises over 200 events across five unique zones around the city’s CBD, all designed to inspire wonder, expand thinking and give each visitor the opportunity to see Sydney in a new light.

Making Vivid Sydney more accessible than ever, over 75 per cent of this year’s program is free to enjoy, including the entire Vivid Light Walk, Martin Place also makes a welcome return to the festival footprint after a seven-year absence.

This year, the world’s biggest names in entertainment, food, and pop culture will feature, including, Martha Stewart, Nigella Lawson, Nick Offerman and Megan Mullally, plus Portishead’s Beth Gibbons.

Minister for Jobs and Tourism Steve Kamper said, “Sydney is ready to shine! As we mark 15 years, this world-class event continues to showcase the very best destinations and creative talent our city has to offer.

“Vivid Sydney continues to grow in scale and impact, drawing millions of visitors and reinforcing Sydney’s position as the premier destination in the Asia Pacific.

“With over 75 per cent of the program free to attend and the entire Vivid Light Walk open to everyone, it is one of the most accessible events in the country, and this year’s program has something for everyone.

“It’s a festival that unites communities, supports local businesses and boosts our visitor and night-time economies. We can’t wait to see the city light up tonight!”

Vivid Sydney 2025 kicked off at Overseas Passenger Terminal in Circular Quay for the annual First Light ceremony, featuring performances by NAISDA dancers that honoured Yolngu culture in Arnhem Land. The ceremony culminated at 6pm as Sydney Harbour burst to life with pyrotechnics, projections and installations illuminating the city’s world-famous buildings and landmarks followed by First Light Live, a free concert honouring the power and pride of First Nations music.   

Vivid Sydney runs from Friday 23 May to Saturday 14 June. For more information visit vividsydney.com.

Japan’s Princess Aiko to Visit Laos in First Official Overseas Trip

Aiko, Princess Toshi, the only daughter of Emperor Naruhito and Empress Masako. (Photo: Yuichi Yamazaki/Getty Images)

Princess Aiko of Japan will visit Laos in November, marking her first official overseas engagement. The visit commemorates the 70th anniversary of diplomatic relations between Japan and Laos, which were established in 1955.

During her trip, Princess Aiko is expected to meet with Lao President Thongloun Sisoulith and attend a commemorative ceremony. The exact date of her visit has not yet been announced.

The daughter of Emperor Naruhito and Empress Masako, Princess Aiko, currently works at the Japanese Red Cross Society and has been gradually taking on more public duties.

While this will be her first official diplomatic trip abroad, she has previously traveled overseas for personal and educational purposes. These include a family trip to the Netherlands in 2006 and a summer study program in the United Kingdom in 2018.

The Japanese Imperial Family has made three previous visits to Laos.

In 1999, Prince and Princess Akishino visited on a goodwill mission. In 2010, Prince Akishino returned with Princess Mako for a cultural and research-focused visit. In 2012, then-Crown Prince Naruhito (now Emperor) visited to observe development projects and meet with Lao leaders.

Six Abstracts of Kelun-Biotech’s Clinical Studies Published at the 2025 ASCO Annual Meeting

CHENGDU, China, May 23, 2025 /PRNewswire/ — The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the “Company”) will present results from six clinical studies, including data on its TROP2 ADC sac-TMT, anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031) during the meeting.

The study abstracts were published on the ASCO website on May 22, 2025 (CDT), with key highlights summarized below:

1. Sac-TMT in patients with previously treated advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study

Oral Presentation: June 1, 10:12-10:24 CDT (Abstract #8507: Lung Cancer – Non-Small Cell Metastatic)

A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks (Q2W)) or docetaxel (75 mg/m2 once every 3 weeks (Q3W)).  The median follow-up of 12.2 months (data cutoff: December 31, 2024).

Sac-TMT achieved statistically significant and clinically meaningful outcomes compare d to docetaxel: confirmed objective response rate (ORR) (blinded independent review committee (BIRC): 45.1% vs 15.6%, one-sided p=0.0004), progression-free survival (PFS) (BIRC: median 6.9 vs 2.8 months, hazard ratio (HR)= 0.30, one-sided p<0.0001; investigator (INV): median 7.9 vs 2.8 months, HR=0.23). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR 0.49, one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36).

Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. No cases of interstitial lung disease (ILD) were reported in sac-TMT group.

These results led to the approval of sac-TMT in EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy in China, which marks the first approval for a TROP2 ADC in lung cancer globally.

2. Sac-TMT as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC): Initial results from the Phase 2 OptiTROP-Breast05 study

Rapid Oral Presentation: May 30, 15:45-15:51 CDT (Abstract #1019: Breast Cancer – Metastatic)

As of November 18, 2024, a total of 41 patients with a/m TNBC who had not received prior treatment for advanced disease (median age 55 years; 43.9% Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 1; 78.0% PD-L1 combined positive score (CPS)<10) were enrolled to receive sac-TMT monotherapy at 5 mg/kg Q2W until disease progression or unacceptable toxicity. The median follow-up was 18.6 months.

The ORR was 70.7% and the disease control rate (DCR) was 92.7%. Median duration of response (DoR) was 12.2 months, while the median PFS was 13.4 months. Among the 32 patients with PD-L1 CPS <10, the ORR was 71.9% and the DCR was 93.8%. The median PFS in this subgroup was 13.1 months.

TRAEs of grade 3 or higher occurred in 63.4% of patients. No treatment-related deaths occurred, and there were no reports of neuropathy or ILD/pneumonitis.

3. Sac-TMT in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced NSCLC: Non-squamous cohort from the Phase 2 OptiTROP-Lung01 study

Poster Presentation: May 31, 13:30-16:30 CDT (Abstract #8529: Lung Cancer – Non-Small Cell Metastatic)

Advanced NSCLC patients with no prior systemic therapy and no actionable genomic alterations were enrolled to receive sac-TMT (5 mg/kg Q3W or Q2W) plus tagitanlimab (1,200 mg Q3W or 900 mg Q2W) until disease progression or unacceptable toxicity. As of December 30, 2024, 81 patients with non-squamous histology were enrolled.

After median follow-up of 17.1 months, confirmed ORR was 59.3%; Median DoR was 16.5 months; Median PFS was 15.0 months. Among patients with PD-L1 tumor proportion score (TPS)≥50%, the confirmed ORR was 77.8%; median PFS was 17.8 months; while for patients with PD-L1 TPS≥1%, the confirmed ORR was 68.1%; median PFS was 17.8 months. Among patients with PD-L1 TPS< 1%, confirmed ORR was 47.1%; median PFS was 12.4 months. Most common Grade≥3 TRAEs were neutrophil count decreased (45.7%), anemia (16.0%), white blood cell count decreased (14.8%) and stomatitis (11.1%). No TRAE led to treatment discontinuation or death.

4. Sac-TMT in patients with previously treated locally advanced or metastatic (LA/M) NSCLC harboring uncommon EGFR mutations: Preliminary results from a Phase 2 Study

Poster Presentation: May 31, 13:30-16:30 CDT (Abstract #8615: Lung Cancer – Non-Small Cell Metastatic)

As of December 1, 2024, 42 advanced NSCLC patients who had progressed on or after systemic therapy were enrolled, including 23 patients with EGFR G719X in exon 18, S768I in exon 20, or L861Q in exon 21 and 19 patients with EGFR ex20ins. Patients received sac-TMT 5 mg/kg Q2W until disease progression or unacceptable toxicity.

After a median follow-up of 9.2 months, the ORR was 35.7% and the DCR was 85.7%. Responses were durable with the median DoR not yet reached. The median PFS was 9.5 months. In the subset of patients with uncommon non-ex20ins, the ORR was 34.8%; the median PFS was 10.9 months. In the subset of patients with ex20ins, the ORR was 36.8% and the median PFS was 9.0 months.

Grade ≥3 TRAEs occurred in 52.4% of patients. No TRAEs led to treatment discontinuation or death. No cases of ILD/pneumonitis were reported.

5. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin (GP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase Phase 3 study

Oral Presentation: May 31, 14:27-14:39 CDT (Abstract #6004: Head and Neck Cancer).

Eligible R/M NPC patients who have not previously received systemic therapy were in 2:1 ratio randomly assigned to receive tagitanlimab or placebo (1200 mg, D1) in combination with cisplatin (80 mg/m2, D1) and gemcitabine (1000 mg/m2, D1 and D8) Q3W for up to 6 cycles followed by tagitanlimab or placebo monotherapy Q3W until disease progression, unacceptable toxicity, or withdrawal of consent. The median follow-up time was 11.7 months.

The PFS per blinded independent central review (BICR) was met with a 53% reduction in risk of progression or death (HR=0.47, one-sided P <0.0001). The median PFS was not reached in tagitanlimab plus GP arm and 7.9 months in placebo plus GP arm. The ORR per BICR was 81.7% in tagitanlimab plus GP arm and 74.5% in placebo plus GP arm, with a median DoR of 11.7 months and 5.8 months (HR=0.48), respectively. The OS benefit was observed in tagitanlimab plus GP arm vs placebo plus GP arm (median OS not reached for either arm; HR=0.62). Tagitanlimab also showed a manageable safety profile.

6. Results from a Phase 1 study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer (MTC)

Poster Presentation: June 2, 9:00-12:00 CDT (Abstract #6098: Head and Neck Cancer)

As of September 20, 2024, 27 advanced RET-mutant MTC patients without prior selective RET inhibitors were enrolled and treated in the phase 1 part across 4 dose levels (20 to 90 mg once a day (QD)). The median follow-up was 19.0 months.

As of September 20, 2024, the confirmed ORR was 63.0% and the DCR was 100% for overall population. The confirmed ORR was 56.3% (9/16) and 62.5% (5/8) in patients with prior multikinase inhibitor (MKI) or treatment naïve, respectively. Median DoR was not reached, with the longest duration still ongoing at 25.8 months. Similarly, median PFS was not reached, with the 24-month PFS rate of 77.8%.

All patients experienced TRAEs, with grade ≥3 TRAEs occurred in 22.2% of patients. No TRAEs led to treatment discontinuation or death.

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestically developed and fully approved for marketing ADC in China with global intellectual property rights. It is also the world’s first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were (to be) reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab[1] or other agents for several types of cancer. These studies are sponsored and led by MSD.

About Tagitanlimab

Tagitanlimab is the first PD-L1 mAb to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively.

About KL590586 ( A400/EP0031)

KL590586(A400/EP0031) is a novel next-generation selective RET inhibitor for NSCLC, MTC and other solid tumors with a high prevalence of RET alterations. The Company are currently conducting pivotal clinical studies for both 1L and 2L+ advanced RET+ NSCLC as well as a phase 1b/2 clinical study for RET+ MTC and solid tumor in China.

In March 2021, The Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries under the code EP0031.

In March 2024, it was announced that EP0031/A400 was granted Fast Track designation by the Food and Drug Administration (FDA) for the treatment of RET-fusion positive NSCLC. In April 2024, EP0031/A400 was cleared by the FDA to progress into Phase 2 clinical development and is now open in the US, UK, EU and UAE.

About Kelun-Biotech

Kelun-Biotech(6990.HK)is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel ADC projects in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

Media: klbio_pr@kelun.com

[1] Pembrolizumab (KEYTRUDA®) is a registered trademark of Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

 

Vientiane Discusses Restoration Plan of Historic Black Stupa

That Dam sign (Photo: Oulayvanh Sisounonth)

The iconic That Dam, or Black Stupa, one of Vientiane’s most culturally significant landmarks, is set to undergo a major restoration as part of a new preservation initiative led by the Lao government.

vivo Expert Dr. Wang Ruixin Wins 3GPP Excellence Award for Outstanding Contribution to 5G OTA Standards

SHENZHEN, China, May 23, 2025 /PRNewswire/ — 3GPP (3rd Generation Partnership Project) formally announced that Dr. Wang Ruixin, a leading telecommunications expert at vivo, has received the prestigious 3GPP Excellence Award 2024 during the 3GPP RAN4#115 meeting held in Malta on May 19, 2025. Presented by 3GPP, an authoritative global communication standards body, the award honors individuals who have made outstanding contributions to the development of mobile communication technology specifications. Dr. Wang’s achievement is an acknowledgment of his technical leadership and underscores vivo’s position as one of the global leaders in 5G core technology R&D and international standard setting.

The 3GPP Excellence Award trophy presented to Dr. Wang Ruixin
The 3GPP Excellence Award trophy presented to Dr. Wang Ruixin

Dr. Wangs Award Recognizes Exceptional Technical Contributions

3GPP is the world’s leading telecommunication standard development body. It currently has more than 850 member companies from over 40 countries, including mobile network operators, equipment manufacturers, instrumentation manufacturers, chipmakers, universities and R&D institutions. The technical specifications produced by 3GPP directly impact the communication experience of billions of users around the world.

Established in 2012, the 3GPP Excellence Award recognizes individuals who have made outstanding technical contributions to the 3GPP working groups. Each year, a maximum of four recipients are selected from all technical specification groups, including Radio Access Networks (RAN), Services & Systems Aspects (SA) and Core Network & Terminals (CT). According to 3GPP statistics, over 1,000 representatives participated in the standard discussions across its working groups in 2024. Dr. Wang stood out with his breakthrough contribution to the field of 5G OTA standards, becoming the second expert from the RAN4 Working Group to receive this honor since the award was established.

The 3GPP Excellence Award ceremony at the RAN4#115 meeting in Malta, May 2025
The 3GPP Excellence Award ceremony at the RAN4#115 meeting in Malta, May 2025

At the award ceremony, the 3GPP RAN4 leadership team highlighted Dr. Wang’s dedication and expertise. “His strong technical expertise, dedication and excellent leadership has made him a successful and outstanding delegate in 3GPP RAN4. Many thanks for Ruixin’s excellent work and contribution!” they stated.

Dr. Wang Ruixin has been actively engaged in 3GPP technical standardization work for many years. In the 5G era, he has served as the Rapporteur for multiple standard projects (WI/SI), leading the development of mobile terminal radiated performance and Over-the-Air (OTA) testing standards. Under his leadership, 3GPP achieved several industry milestones in this field, including the finalization of 5G UE OTA requirements in 2024 – a groundbreaking accomplishment in the industry.

Beyond his individual technical contributions, as vivo’s prime delegate of RAN4 working group, Dr. Wang has led the vivo RAN4 team participation in technical discussions across multiple topics, actively driving the development of 3GPP standards.

From Technical Breakthroughs to Ecosystem Building: vivo’s Methodology for Standard Innovation

Dr. Wang’s achievements reflect vivo’s systematic investment in the field of communication technology. As a global leader in smartphone manufacturing, vivo established the Communications Research Institute in 2016, focusing on cutting-edge mobile communication research, international/industry standard development, and core technology verification and testing for the group.

To date, vivo has submitted over 17,000 5G technical proposals to 3GPP, participated in the formulation of more than 700 technical standards, and applied for over 7,000 patents for 5G and 6G technologies. It has successfully driven projects such as UE power saving, Multi-SIM, LP-WUS, and narrowband voice satellite communication within 3GPP. vivo has also developed prototypes for 5.5G and 6G technologies, including NTN, RedCap, AI+ communication, 6G mobile computing-network integration, 6G integrated sensing and communication, 6G data plane, and 6G backscatter technologies. Additionally, vivo has published six 6G white papers and three technical books through People’s Posts & Telecommunications Press, making outstanding contributions to the formulation of global mobile communication standards and the advancement of the industry.

With its achievements and contributions in 5G standard setting, technology validation, testing, product development, and application, vivo was awarded the National Science and Technology Progress Award First Prize in June 2024, consolidating its leading position in the field of global communication technology.

Dr. Wang’s 3GPP Excellence Award marks a career milestone and demonstrates vivo’s innovation leadership. As the global communication industry steps into a new decade of “intelligent connectivity for all”, innovation pioneers like vivo are writing a new chapter in the history of world communications.

About vivo

vivo is a technology company driven by design to create exceptional products, with smart terminals and intelligent services at its core. It aims to bridge the gap between people and the digital world, offering users a more convenient and personalized mobile digital life. Guided by its corporate values of ‘Benfen’ (staying grounded), user orientation, design-driven innovation, continuous learning, and teamwork, vivo integrates sustainable development strategies across its value chain, striving to become a healthier, enduring world-class enterprise.

Headquartered in Dongguan, China, vivo taps into local talent resources and maintains an extensive R&D network spanning Shenzhen, Dongguan, Nanjing, Beijing, Hangzhou, Shanghai, and Xi’an. Its research covers a wide range of frontier areas, including 5G communication, artificial intelligence, industrial design, and imaging technology. Currently, vivo’s manufacturing network (including authorized production) boasts an annual production capacity of nearly 200 million units, with sales covering over 60 countries and regions and a user base exceeding 500 million.

For more corporate, brand, product, and technology updates, follow vivo’s official WeChat accounts: ‘vivo’ and ‘XG Detective Agency’.

For additional media resources, high-resolution images, or videos, please visit: https://mobile.vivo.com/

Moldova to Host the 46th World Congress of Vine and Wine – in the Country with the Highest Vineyard Density per Capita

What You Should Know About This Wine Nation

CHIȘINĂU, Moldova, May 23, 2025 /PRNewswire/ — This year, the World Congress of Vine and Wine will take place for the first time in the Republic of Moldova – the country with the highest vineyard area per capita in the world, with 4 hectares for every 100 people. Moldova’s total vineyard area reaches nearly 110,000 hectares. The country ranks among the top 20 wine producers globally and is the 14th largest wine exporter in the world.

46th Congress of Vine and Wine
46th Congress of Vine and Wine

In 2024, Moldova exported 144 million liters of wine, worth over 234 million USD. Moldovan wines are shipped to 73 countries, with half of all exports going to European markets. In Moldova, wine is not just an industry – it is part of the country’s identity, history, and economy. Over the past few years, the wine sector has grown significantly, thanks to high quality and improved wine tourism infrastructure. Moldova now has over 250 wineries, offering great wines and unforgettable experiences for visitors from around the world.

Moldova has built a strong reputation in the international wine world not only through its authentic terroir and ancient traditions, but also through the growing recognition it has earned in recent decades. In the past five years, Moldovan wines have won thousands of medals at top global competitions – including Berliner Wine Trophy, Mundus Vini, Decanter World Wine Awards, and Concours Mondial de Bruxelles. These awards have helped Moldova become known as a serious producer of high-quality wines, able to compete internationally and impress even the most demanding wine experts.

A major milestone in promoting Moldovan wines abroad was the creation of the National Office of Vine and Wine (ONVV) and the launch of the national brand “Wine of Moldova: Unexpectedly Great” in 2013.

The 46th edition of the World Congress of Vine and Wine will take place from June 16 to 20, 2025, at the Palace of the Republic in Chișinău, Moldova. The congress will bring together 300 experts, researchers, winemakers, oenologists, producers, and policymakers from 51 member countries of the OIV, to discuss the future of the global wine industry.

Participants will also take part in 13 technical visits to Moldova’s most renowned wineries, and enjoy a festive dinner hosted at Cricova – the world-famous underground wine city known for its vast tunnels and excellent wines.

Participation packages are available for purchase on the official congress website:
https://oiv2025.md/packages-available/

The event is organized by the International Organisation of Vine and Wine (OIV), in collaboration with the Ministry of Agriculture and Food Industry of Moldova and the National Office for Vine and Wine (ONVV). Moldova has been a member of the OIV since April 3, 2001 – the first country from the CIS to join the organization. In 2024, the OIV celebrates its 100th anniversary, and the congress in Moldova marks the beginning of its second centenary.

Department of International Trade Promotion, Ministry of Commerce, promotes Thai film industry through Thai Night 2025 at Cannes Film Festival, France.


CANNES, FRANCE – Media OutReach Newswire – 23 May 2025 – The Department of International Trade Promotion (DITP), Ministry of Commerce, successfully organized Thai Night 2025, an event aimed at enhancing the global presence of the Thai entertainment industry and promoting international business networking. The event took place on Thursday, May 15, 2025, during the renowned Cannes Film Festival – one of the world’s most prestigious international film festivals. Her Royal Highness Princess Ubolratana Rajakanya Sirivadhana Barnavadi presided over the ceremony, delivered an inspiring keynote address and extended a warm welcome to distinguished guests, including producers, directors, content creators, and media representatives from around the world.

Thai Night Cannes 2025
Thai Night Cannes 2025

In her remarks, Her Royal Highness highlighted the exponential growth of the Thai film industry in 2024, calling it a remarkable year in which domestic revenue from Thai films surpassed 1 billion baht for the first time – an unprecedented achievement that reflects the exceptional talent and creativity of Thai filmmakers. Thai films now hold a domestic market share of nearly 50%, on par with foreign films, demonstrating the industry’s ability to compete on the global stage.

Thai Night 2025 attracted over 300 prominent figures from the international film industry, including buyers, directors, investors, renowned actors, celebrities, and media representatives. The top five countries represented were France, the United States, the United Kingdom, Hong Kong, and Germany – reflecting Thailand’s strong cultural and industry tie with major global film markets. The event served as a vital platform to showcase the achievements, creativity, and growing potential of the Thai film industry.

The successes of 2024 underscore the innovation and dedication of Thai filmmakers, who continue to captivate audiences both at home and abroad with compelling narratives across genres such as drama, horror, comedy, and LGBTQ+ stories. These works serve as powerful instruments of soft power, effectively showcasing Thai culture to the world. Thai Night 2025 also highlighted Thailand’s strengths as a leading film production hub, including its diverse locations, skilled professionals, attractive production incentives, and the unique charm that makes the country a preferred destination for international filmmakers.

In addition to the gala event, the DITP further supported the Thai film industry through the Thai Pavilion at the Palais des Festivals et des Congrès de Cannes, held from May 13-21, 2025. The pavilion served as a venue for showcasing filmmaking process and facilitating business matching and film trading between Thai producers, film service providers, and global partners. These initiatives reinforce Thailand’s readiness to take a prominent place on the global film stage and gain greater international recognition.

Hashtag: #DITP #ThaiNight

The issuer is solely responsible for the content of this announcement.

Tuniu Announces Receipt of Minimum Bid Price Notice from Nasdaq

NANJING, China, May 23, 2025 /PRNewswire/ — Tuniu Corporation (Nasdaq: TOUR) (“Tuniu” or the “Company”), a leading online leisure travel company in China, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated May 19, 2025, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s American depositary shares (the “ADSs”) was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Nasdaq notification letter has no current effect on the listing or trading of the Company’s securities on the Nasdaq Global Market.

Pursuant to the Nasdaq Listing Rules 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days, or until November 17, 2025, to regain compliance under the Listing Rules. If at any time during the 180-day compliance period, the closing bid price of the Company’s ADSs is US$1.00 per share or higher for a minimum of ten consecutive business days, the Nasdaq will provide the Company written confirmation of compliance and the matter will be closed.

In the event the Company does not regain compliance by November 17, 2025, subject to the determination by the staff of Nasdaq, the Company may be eligible for an additional 180-day compliance period.

The Nasdaq notification letter will have no effect on the Company’s business operations, and the Company will take all reasonable measures to regain compliance.

About Tuniu

Tuniu (Nasdaq: TOUR) is a leading online leisure travel company in China that offers integrated travel service with a large selection of packaged tours, including organized and self-guided tours, as well as travel-related services for leisure travelers through its website tuniu.com and mobile platform. Tuniu provides one-stop leisure travel solutions and a compelling customer experience through its online platform and offline service network, including a dedicated team of professional customer service representatives, 24/7 call centers, extensive networks of offline retail stores and self-operated local tour operators. For more information, please visit http://ir.tuniu.com.

Safe Harbor Statement

This press release contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Tuniu may also make written or oral forward-looking statements in its reports filed with or furnished to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to fourth parties. Any statements that are not historical facts, including statements about Tuniu’s beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but are not limited to the following: Tuniu’s goals and strategies; the growth of the online leisure travel market in China; the demand for Tuniu’s products and services; its relationships with customers and travel suppliers; Tuniu’s ability to offer competitive travel products and services; Tuniu’s future business development, results of operations and financial condition; competition in the online travel industry in China; government policies and regulations relating to Tuniu’s structure, business and industry; the impact of health epidemics on Tuniu’s business operations, the travel industry and the economy of China and elsewhere generally; and the general economic and business condition in China and elsewhere. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is current as of the date of the press release, and Tuniu does not undertake any obligation to update such information, except as required under applicable law.